Epilepsy in the pediatric population presents unique challenges in terms of diagnosis,management, and treatment, requiring careful consideration of pharmacokinetics,safety, and developmental factors. Although advances in antiepileptic drugs (AEDs) have significantly improved the management of epilepsy in children,treatment options remain limited, and many existing medications are not specificallyapproved for pediatric use. This review examines current drug development strategiesfor pediatric epilepsy, with a focus on recent advances in the discovery and clinicaltesting of novel AEDs. It highlights the importance of age-appropriate formulations,dosing regimens, and the consideration of coexisting conditions such asneurodevelopmental disorders. The review also addresses the key challenges faced in pediatric clinical trials, including ethical considerations, recruitment, and the need for biomarkers to guide therapy. Special attention is given to recentinnovations in personalized medicine, including the potential of genetic testingand precision therapies for optimizing treatment outcomes in pediatric epilepsy. Finally,we discuss the unmet needs in pediatric epilepsy drug development, emphasizing theneed for safer, more effective treatments with fewer side effects to improve quality oflife and long-term prognosis for affected children.